Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company focused on advanced therapies for the sports medicine and severe burn care markets. Its news flow centers on financial performance, adoption of its cell therapy and biologic products, and progress in clinical and manufacturing initiatives.
Investors following VCEL news can expect regular quarterly earnings releases detailing total revenue, product-level revenue for MACI and Burn Care (Epicel and NexoBrid), gross margin, net income or loss, adjusted EBITDA and operating cash flow. Vericel frequently provides financial guidance ranges for full-year revenue, MACI growth, gross margin and adjusted EBITDA margin, and may update these expectations as the year progresses.
Company updates also highlight operational metrics such as record MACI revenue, numbers of MACI implants and biopsies, growth in trained MACI Arthro surgeons, Epicel and NexoBrid biopsy and hospital order trends, and expansion of the MACI sales force. These disclosures offer insight into market penetration and utilization of Vericel’s therapies in orthopedic and burn care settings.
Vericel news items often include information on clinical and regulatory milestones, such as FDA IND clearance for the Phase 3 MACI Ankle clinical study and the initiation of the MACI Ankle MASCOT clinical trial. The company also announces participation in major investor and healthcare conferences, including events hosted by J.P. Morgan, Stephens, Wells Fargo and Truist Securities, where management discusses business performance and strategy.
This VCEL news page aggregates these press releases and related announcements so readers can review historical and recent developments around Vericel’s financial results, product adoption, clinical programs and corporate presentations in one place.
Vericel Corporation (NASDAQ: VCEL) announced on September 16, 2020, that the FDA has accepted its Biologics License Application for NexoBrid® to treat deep partial-thickness and full-thickness thermal burns. The FDA set a PDUFA target date of June 29, 2021, without plans for an advisory committee meeting. CEO Nick Colangelo emphasized the significance of this milestone in establishing a new standard of care for burn treatment, while MediWound's CEO expressed gratitude to partners involved in the development. Vericel will host a virtual Analyst and Investor Day on October 16, 2020, to discuss NexoBrid's potential impact.
Vericel Corporation (NASDAQ: VCEL) announced that Nick Colangelo, its President and CEO, will present at the 18th Annual Morgan Stanley Global Healthcare Conference on September 17, 2020, at 2:45 p.m. ET. The conference will be conducted virtually, and the presentation will be accessible via a live webcast on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, with products like MACI® and Epicel®. The company also holds exclusive North American rights to NexoBrid® for burn treatment.
Vericel Corporation (NASDAQ: VCEL) announced a significant procurement from BARDA of $16.5 million for NexoBrid, aimed at enhancing U.S. preparedness for burn incidents. This initial shipment marks a critical milestone in its partnership with BARDA, with more deliveries planned through 2021. NexoBrid is designed for emergency treatment of severe burns and has been submitted for FDA approval. Vericel and MediWound will split the profits from this procurement, which is part of a long-term contract initiated in 2015 to develop and provide medical countermeasures for mass casualty situations.
Vericel Corporation (NASDAQ: VCEL) announced a conference call to discuss its second-quarter 2020 financial results scheduled for August 5, 2020, at 8:30 am EDT. The call will be accessible via the company’s website and through a telephone line for participants. Vericel specializes in advanced therapies in sports medicine and severe burn care, marketing products such as MACI® and Epicel®. The conference will provide insights into the company’s financial performance and business outlook for the upcoming period.
Vericel Corporation (NASDAQ: VCEL) submitted a Biologics License Application (BLA) to the FDA for NexoBrid®, aimed at treating adults with thermal burns through eschar removal. The submission is supported by the pivotal Phase 3 DETECT study, which demonstrated significant benefits over standard care, including faster eschar removal and lower blood loss. NexoBrid is already approved in the EU and other markets. Vericel holds exclusive North American rights, with development support from BARDA.
Vericel Corporation (NASDAQ: VCEL) will present a company overview at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 12:30 PM Eastern Time. Nick Colangelo, the company's president and CEO, will be leading the presentation. A live webcast will be accessible on Vericel's Investor Relations website for those interested in learning more about the company's advancements in sports medicine and severe burn care. Vericel is recognized for its products, MACI® and Epicel®, and its license for NexoBrid®.